October 04, 2017

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs

Read More
September 26, 2017

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Read More
September 20, 2017

Selexis SA, Spinomix SA and the University of Lausanne Publish Novel, High-Throughput Technology Process for Isolation of High Secretion CHO Cell Clones

Read More
September 05, 2017

Selexis to Participate at Several Upcoming Industry Conferences

Read More
June 27, 2017

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Read More